.jpg "Tarik Asselah, MD PhD photo")
Professor of Hepatology, Head of Viral Hepatitis
Université de Paris-Cité. Hôpital Beaujon, Paris, France., France
Disclosure(s): AbbVie: Speaker/investigator; Eiger Biopharmaceutical: Speaker/investigator; Gilead Sciences, Inc.: Speaker/investigator; Janssen: Speaker/investigator; Merck: Speaker/investigator; Myr Pharmaceutical: Speaker/investigator; Roche: Speaker/investigator
Tarik Asselah is a Full Professor of Medicine and Hepatology, caring for patients at Hôpital Beaujon, Assitance Publique des Hôpitaux de Paris (AP-HP), Clichy, France, and teaching at the University of Paris-Cité, France. Professor Asselah is the Head of Viral Hepatitis at Institut national de la santé et de la recherche médicale (INSERM ; UMR 1149), Centre de Recherche sur l’Inflammation). He is an MD and also holds a PhD in virology.
Prof. Asselah’s fields of research include chronic liver diseases, translational medicine, precision medicine, and treatment of viral hepatitis (HBV, HCV and HDV). Prof. Asselah is a coordinator/principal investigator for many international clinical trials of therapies for chronic viral hepatitis with particular interest in early phase development (from phase I to III) of new direct acting antiviral therapies. Prof. Asselah has coordinated at the international level major international clinical trials on viral hepatitis, such as Solstice (NCT05461170, Vir Biotechnology), MYR-204 (NCT03852433, Gilead), Octopus (NCT05275023, Janssen), and Endurance-4 (NCT02636595, AbbVie) studies. Prof. Asselah was an expert for the European Association for the Study of the Liver (EASL) Clinical Practice Guidelines on hepatitis delta virus in 2023.
Prof. Asselah has authored more than 300 articles in the field of chronic liver diseases in major journals (The New England Journal of Medicine, The Lancet, Gastroenterology, Hepatology, Journal of Hepatology, etc…) with over 15,000 total citations (H-index = 61). He has been selected as a Rising Star in Gastroenterology in 2009 by the United European Gastroenterology (UEG) in appreciation of his outstanding scientific work. He received awards for his genomic studies on HCV in 2005 from the French Association for Liver Disease (AFEF), and for his leadership in hepatology in 2019 from the Czech Hepatology Society. In 2023, Prof. Asselah received the Faculty Outstanding Research Output Award from the Li Ka Shing Faculty of Medicine of Hong Kong. In 2024, Prof. Asselah received the Presidential Award from the Asian Pacific Association for the Study of the Liver (APASL) 2024 in Kyoto, Japan.